Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Objectives: Cyclooxygenase-2 (COX-2) overexpression in locally advanced head and neck cancer and preclinical benefit for COX-2 inhibitors with radiotherapy (RT) led us to study weekly doublet chemotherapy, daily radiotherapy, and celecoxib. Follow-up data on response and tolerability at a median of 20.5 months are presented.
Methods: Eligibility: stage III or IV squamous cell cancer of oral cavity, oropharynx, hypopharynx, larynx; performance status 0, 1, 2; adequate hepatic, hematologic, renal function; and no prior radiotherapy/chemotherapy for this site. Treatment: weekly docetaxel (T), 12.5 mg/m2, and cisplatin (P), 20 mg/m2 intravenously, on day 1 for 6 weeks; and RT, single fraction, on days 1-5 for 7 weeks or to total standard dose (70 Gy); and celecoxib (C), 400 twice daily by mouth. Feeding tubes were placed prophylactically.
Axelrod RS, Machtay M, Anne PR, Dicker A, Sidhu K, Jacobs M, Rosen M, Keane W. P015 Phase 1: Update of Weekly Docetaxel, Cisplatin, Daily Celecoxib, Concurrent Radiotherapy in Advanced Head and Neck Cancer. Arch Otolaryngol Head Neck Surg. 2006;132(8):869. doi:10.1001/archotol.132.8.869-a